Alnylam Pharmaceuticals Portfolio, Stock and Financial Highlights: Expected Approval of OXLUMO™ (lumasiran) and LEQVIO® (inclisiran) By End of 2020

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. 
The commercially approved products include
  • ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and 
  • GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). 
Platform
RNAi therapies leverage two distinct approaches to enable the delivery of small interfering Ribonucleic Acid (siRNA): lipid nanoparticles (LNP) and GalNAc-conjugates

Stock Symbol: ANLY

Therapeutic Area (Late Stage)


Q3 2020 Highlights 
  • ONPATTRO® Global Net Product Revenue of $82.5 Million, 
  • GIVLAARI® Global Net Product Revenue of $16.7 Million
  • Received Positive Opinions for OXLUMO™ (lumasiran) and LEQVIO® (inclisiran) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
Net Product Revenues
Net product revenues were $99.2 million in the third quarter 2020 representing 115% growth from the third quarter 2019

Net Revenues from Collaborations
Net revenues from collaborations were $26.6 million in the third quarter 2020, an increase from $24.0 million in the third quarter 2019

Cash and Investments
Cash, cash equivalents and marketable securities were $1.83 billion at the end of the third quarter 2020 compared to $1.54 billion at the end of 2019.

For detail, visit https://www.alnylam.com



Pages You May Like